• 患者服务: 与癌共舞小助手
  • 微信号: yagw_help22

QQ登录

只需一步,快速开始

开启左侧

我父亲肺鳞癌的治疗贴(2014年3月1日驾鹤西去)

    [复制链接]
1245509 1620 老马 发表于 2011-10-27 08:05:18 | 置顶 |
老马  博士一年级 发表于 2012-4-27 18:50:42 | 显示全部楼层 来自: 浙江温州
Pooled Analysis of S-1 Trials in Non-Small Cell Lung Cancer According to Histological Type
7 O/ k5 [* T# V- sNOBUYUKI YAMAMOTO1, TAKEHARU YAMANAKA2, YUKITO ICHINOSE3, KAORU KUBOTA4, HIROSHI SAKAI5, AKIHIKO GEMMA6, NAGAHIRO SAIJO7, MASAHIRO FUKUOKA8 and HISANOBU NIITANI9 ( o5 u6 v& g6 |8 |/ m6 A
+ Author Affiliations9 R8 Q* n% o7 \6 T1 x9 o
' U, m2 r' c, ^: |. B- I
1Division of Thoracic Oncology, Shizuoka Cancer Center, Shizuoka 411-8777, Japan ; M5 D. D7 ^. M, U/ y2 P5 q4 D, I) N
2Cancer Biostatistics Laboratory, Institute for Clinical Research, National Kyushu Cancer Center, Fukuoka 811-1395, Japan
' U- e! m: F% K2 q3Department of Thoracic Oncology, National Kyushu Cancer Center, Fukuoka 811-1395, Japan 0 e% t, J' w. |
4Division of Thoracic Oncology, National Cancer Center Hospital, Tokyo 104-0045, Japan
2 e& v4 u2 s+ a  q5Division of Thoracic Oncology, Saitama Cancer Center, Saitama 362-0806, Japan
  m- [5 o3 C8 W5 {$ S% [6Division of Pulmonary Medicine, Infectious Diseases, and Oncology Department of Internal Medicine, Nippon Medical School, Tokyo 113-8603, Japan . K% J% ^, o, o- [, {7 q5 `/ A( r- k
7Kinki University School of Medicine, Osaka 589-8511, Japan ! I  z7 f- Z2 g# e3 O
8Izumi Municipal Hospital, Osaka 594-0071, Japan ! g4 H! T0 L+ C& n. t; B
9Tokyo Cooperative Oncology Group, Tokyo 105-0013, Japan
2 `6 t$ |. C4 d) [8 P# o+ |Correspondence to: Nobuyuki Yamamoto, Division of Thoracic Oncology, Shizuoka Cancer Center, 1007 Shimonagakubo, Nagaizumi-cho, Sunto-gun, Shizuoka 411-8777, Japan. Tel: +81 559895222, Fax: +81 559895783, e-mail: n.yamamoto@scchr.jp * T6 _7 Y0 H; a9 `
AbstractBackground: The antimetabolic agent S-1 inhibits thymidylate synthase similar to pemetrexed, but through a different mechanism of action. Whether the antitumour activity of S-1 depends on histological type remains unclear. We analysed pooled data from 2 phase II clinical studies of cisplatin and S-1 in patients with previously untreated advanced non-small cell lung cancer. Patients and Methods: We comprised 110 patients with stage IIIB or IV non–small cell lung cancer. Univariate and multivariate analyses were performed to determine the effects of histological type on progression-free survival and response rates. Results: On pooled analysis of the data, according to histological type, median progression-free survival was 3.8 months in patients with squamous cell carcinoma and 4.4 months in those with non-squamous cell carcinoma. Both analyses showed that progression-free survival and response rate did not differ significantly. Conclusion: Unlike molecular targeted agents and pemetrexed, a combination of cisplatin and S-1 may be no difference in response according to histological type. 2 M) a2 ~7 _3 q' n) F7 @4 `

3 u9 b$ ?# p" w5 B& n; h0 {
个人公众号:treeofhope
老马  博士一年级 发表于 2012-4-27 18:52:43 | 显示全部楼层 来自: 浙江温州
S-1 monotherapy for previously treated non-small cell lung cancer: A retrospective analysis by age and histopathological type $ n1 |  f4 V5 O& S) c& W
% Y# h; K2 Z. W3 I1 m2 L
Authors: Yuki Tomita, Tetsuya Oguri, Osamu Takakuwa, Makoto Nakao, Eiji Kunii, Takehiro  Uemura, Hiroaki Ozasa, Mikinori Miyazaki, Ken Maeno, Shigeki Sato : l& ?9 l/ ^. X. _/ c4 m8 [

7 O% F" n6 o$ v" k& w: x9 BAffiliations: Department of Medical Oncology and Immunology, Nagoya City University Graduate School of Medical Sciences, Mizuho-cho, Mizuho-ku, Nagoya, Aichi 467-8601, Japan  
4 Z2 ^/ z8 b& A- A# L5 X3 q! f3 K2 M5 f7 u
Published online on: Thursday, December 1, 2011
9 w3 f1 a( t$ J& ~* q3 Z$ C% B- T% _: r8 k8 a( v- n
Doi: 10.3892/ol.2011.507
7 J  q: C1 Q3 W/ K/ A% {( |2 M* D: s& f0 u
Pages: 405-410 # C2 \) {& R. M) U) D
" M* n% a4 t1 O- u! F$ o
Abstract:1 O/ V4 p. y1 g8 \
S-1, an oral fluoropyrimidine derivative, has been approved for the treatment of non-small cell lung cancer (NSCLC) in Japan. In the present study, the efficacy and safety of S-1 monotherapy for elderly patients with previously treated NSCLC were retrospectively evaluated, and the efficacy of S-1 monotherapy was compared by histopathological type. This retrospective study included 54 patients with advanced or recurrent NSCLC who had received S-1 monotherapy following the failure of previous chemotherapy regimens at our institutes. Patient outcomes were compared based on their age and histopathological type. S-1 was administered orally, twice daily, while the duration and interval were modified according to the medical condition of each patient. The default delivery schedule, the mean number of S-1 cycles, did not differ significantly between the two age groups (<70 and ≥70 years). The rate of therapy discontinuation, schedule modification or dose reduction due to intolerable toxicities or patient refusal was relatively frequent in the older group (40.7 and 55.6% for ages <70 and ≥70 years, respectively; p=0.414), and the incidence of grade 3 anemia was relatively high in the older group (3.7 and 18.5%, respectively; p=0.192). The response rates (13.0 and 4.8%, respectively; p=0.609) and disease control rates (39.1 and 33.3%, respectively; p=0.761) did not differ significantly between the two age groups. According to histopathological type, the disease control rate was significantly higher in adenocarcinoma (57.9%) compared to non-adenocarcinoma (20.0%, p=0.013). Thus, S-1 monotherapy may be equally effective and tolerated in patients <70 years and those ≥70 years. Additionally, adenocarcinoma may have a higher disease control rate than non-adenocarcinoma.
" v& D. {+ H# `  O3 N1 R : O) g# z! p! ~! a; z
个人公众号:treeofhope
老马  博士一年级 发表于 2012-4-27 18:57:27 | 显示全部楼层 来自: 浙江温州
Thymidylate synthase (TS) gene expression in primary lung cancer patients: a large-scale study in Japanese population
9 a5 n6 d% s8 |. Z1 n* n9 {F. Tanaka1,*, H. Wada2, Y. Fukui3 and M. Fukushima3 " |8 j7 v' C" o0 |$ L, N+ Q/ h" s
+ Author Affiliations( H  J) I; x0 S& C" W
1Second Department of Surgery, University of Environmental and Occupational Health, Kitakakyushu ( y6 c6 `8 Y9 ~. M# |. E
2Department of Thoracic Surgery, Kyoto University, Kyoto 6 D! a( p2 f. b. T% p  J
3Tokushima Research Center, Taiho Pharmaceutical Co. Ltd, Tokushima, Japan
  P+ p8 c2 r/ e7 k# k, ~&#8629;*Correspondence to: Dr F. Tanaka, Second Department of Surgery, University of Environmental and Occupational Health, 1-1 Isegaoka, Yahata-nishi, Kitakakyushu, 807-8555, Japan. Tel: +81-93-891-7442; Fax: +81-93-692-4004; E-mail: ftanaka@med.uoeh-u.ac.jp
( ^1 D) d% e1 @8 }Received September 3, 2010. # {6 I' m1 S9 d9 H! I5 i  c
Revision received November 11, 2010.
0 Q7 f1 f) }/ [0 C4 q, K9 {Accepted November 17, 2010.
5 M# j$ |% I; N- a2 \. FAbstract
  r. i+ ], v- t- [" o& R1 T, nBackground: Previous small-sized studies showed lower thymidylate synthase (TS) expression in adenocarcinoma of the lung, which may explain higher antitumor activity of TS-inhibiting agents such as pemetrexed. 6 Y2 b" f, \# k6 B2 _' c1 ?! J+ R4 w
Patients and methods: To quantitatively measure TS gene expression in a large-scale Japanese population (n = 2621) with primary lung cancer, laser-captured microdissected sections were cut from primary tumors, surrounding normal lung tissues and involved nodes.
# U% x: d9 {$ T: M% uResults: TS gene expression level in primary tumor was significantly higher than that in normal lung tissue (mean TS/β-actin, 3.4 and 1.0, respectively; P < 0.01), and TS gene expression level was further higher in involved node (mean TS/β-actin, 7.7; P < 0.01). Analyses of TS gene expression levels in primary tumor according to histologic cell type revealed that small-cell carcinoma showed highest TS expression (mean TS/β-actin, 13.8) and that squamous cell carcinoma showed higher TS expression as compared with adenocarcinoma (mean TS/β-actin, 4.3 and 2.3, respectively; P < 0.01); TS gene expression was significantly increased along with a decrease in the grade of tumor cell differentiation. There was no significant difference in TS gene expression according to any other patient characteristics including tumor progression. 2 W$ f- e- N# i" X; H. \
Conclusion: Lower TS expression in adenocarcinoma of the lung was confirmed in a large-scale study.
: x% ^  o0 b7 Y' H9 v$ ~" E
个人公众号:treeofhope
走在异乡  高中一年级 发表于 2012-4-28 00:30:22 | 显示全部楼层 来自: 四川成都
一直关注老马的帖子,前方的指明灯。祝福你爸好疗效
累计签到:1 天
连续签到:1 天
[LV.1]初来乍到
baiselianyi  初中二年级 发表于 2012-4-28 10:24:44 | 显示全部楼层 来自: 浙江台州
一直得到老马帮助,祝福老马爸爸
老马  博士一年级 发表于 2012-4-28 18:00:37 | 显示全部楼层 来自: 浙江温州
26日吃了12片地米(0.75mg一片),27日吃了22片地米(0.75mg 一片),28日吃了12片地米(0.75mg一片),都分二次吃。' a8 O# p4 f$ C$ g
今天为止没有任何反应,每天吃VC,VB2,还有漱口水,就怕口腔溃疡。
个人公众号:treeofhope
bishop_cn  大学一年级 发表于 2012-4-28 23:16:11 | 显示全部楼层 来自: 中国
副作用如何,单药反应很小吧?
1 ^% Q  E- c8 i  _* h
老马  博士一年级 发表于 2012-4-29 00:20:00 | 显示全部楼层 来自: 浙江温州
LUX-Lung 8: A Phase III Trial of Afatinib (BIBW 2992) Versus Erlotinib for the Treatment of Squamous Cell Lung Cancer After at Least One Prior Platinum Based Chemotherapy
' n* c) O4 X/ u' T; A3 Ehttp://clinicaltrials.gov/ct2/show/NCT01523587& l! K. |. j8 q

3 N3 E9 n5 z3 [BIBW 2992 Plus Simvastatin vs. BIBW 2992 in Previously Treated Patients With Advanced Non-adenocarcinomatous NSCLC$ D9 p% Q: ~/ U9 z& d
http://clinicaltrials.gov/ct2/show/NCT01156545
个人公众号:treeofhope
老马  博士一年级 发表于 2012-4-29 20:53:58 | 显示全部楼层 来自: 浙江温州
本帖最后由 老马 于 2012-4-30 09:33 编辑 5 J- z5 J+ Q/ _

' x3 x0 J7 z! F从4月24日开始到4月28日,打了5天的舒普深(注射用头孢哌酮钠舒巴坦钠),效果非常好。2 w" x+ l: V" z% y: i& G9 i5 `: B) w% L
至今为止,未出现化疗副作用。
个人公众号:treeofhope
英雄武松  大学四年级 发表于 2012-4-30 01:37:05 | 显示全部楼层 来自: 哈萨克斯坦
老马 发表于 2012-4-29 20:53
% F0 N3 Q5 ^0 u0 C0 `1 n! M) X. z从4月24日开始到4月28日,打了5天的打了5天舒普深(注射用头孢哌酮钠舒巴坦钠),效果非常好。
: }4 \+ x$ e' \# _( V至今为止,未出 ...
: d9 H* ~, t5 N4 a+ m: x; M  K' {
没有副作用是第一追求,效果显著是第二追求。; c0 X% r  n2 j; [+ L2 A
不错。

发表回复

您需要登录后才可以回帖 登录 | 立即注册

本版积分规则

  • 回复
  • 转播
  • 评分
  • 分享
帮助中心
网友中心
购买须知
支付方式
服务支持
资源下载
售后服务
定制流程
关于我们
关于我们
友情链接
联系我们
关注我们
官方微博
官方空间
微信公号
快速回复 返回顶部 返回列表